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IslBACKGROUND Levels of atherogenic lipoproteins achieved with statin therapy are highly variable, but the
consequence of this variability for cardiovascular disease risk is not well-documented.
OBJECTIVES The aim of this meta-analysis was to evaluate: 1) the interindividual variability of reductions in low-
density lipoprotein cholesterol (LDL-C), non–high-density lipoprotein cholesterol (non-HDL-C), or apolipoprotein B
(apoB) levels achieved with statin therapy; 2) the proportion of patients not reaching guideline-recommended lipid levels
on high-dose statin therapy; and 3) the association between very low levels of atherogenic lipoproteins achieved with
statin therapy and cardiovascular disease risk.
METHODS This meta-analysis used individual patient data from 8 randomized controlled statin trials, in which con-
ventional lipids and apolipoproteins were determined in all study participants at baseline and at 1-year follow-up.
RESULTS Among 38,153 patients allocated to statin therapy, a total of 6,286 major cardiovascular events occurred
in 5,387 study participants during follow-up. There was large interindividual variability in the reductions of LDL-C,
non-HDL-C, and apoB achieved with a ﬁxed statin dose. More than 40% of trial participants assigned to high-dose statin
therapy did not reach an LDL-C target <70 mg/dl. Compared with patients who achieved an LDL-C >175 mg/dl, those
who reached an LDL-C 75 to <100 mg/dl, 50 to <75 mg/dl, and <50 mg/dl had adjusted hazard ratios for major car-
diovascular events of 0.56 (95% conﬁdence interval [CI]: 0.46 to 0.67), 0.51 (95% CI: 0.42 to 0.62), and 0.44 (95% CI:
0.35 to 0.55), respectively. Similar associations were observed for non-HDL-C and apoB.
CONCLUSIONS The reductions of LDL-C, non-HDL-C, and apoB levels achieved with statin therapy displayed large
interindividual variation. Among trial participants treated with high-dose statin therapy, >40% did not reach an LDL-C
target <70 mg/dl. Patients who achieve very low LDL-C levels have a lower risk for major cardiovascular events than do
those achieving moderately low levels. (J Am Coll Cardiol 2014;64:485–94) © 2014 by the American College of
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ABBR EV I A T I ON S
AND ACRONYMS
apo = apolipoprotein
CHD = coronary heart disease
CVD = cardiovascular disease
HDL-C = high-density
lipoprotein cholesterol
LDL-C = low-density
lipoprotein cholesterol
MI = myocardial infarction
non-HDL-C = non–high-density
lipoprotein cholesterol
PCSK9 = proprotein
convertase subtilisin/kexin 9
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486T here is a wealth of evidence thathigh-dose statin therapy reducesboth levels of atherogenic lipopro-
teins and cardiovascular disease (CVD) risk
beyond that achieved with usual-dose statin
therapy (1). However, the evidence on the ef-
ﬁcacy of statin therapy is interpreted on the
basis of mean reductions of low-density lipo-
protein cholesterol (LDL-C) and mean reduc-
tions of CVD risk within randomized trials.
There is large interindividual variation in
the extent of reduction of atherogenic lipo-
protein levels achieved with statin therapy.
Post-hoc analyses of randomized trials sug-
gest that the beneﬁts of statin therapy dependon the extent of achieved LDL-C reduction (2,3). In
addition, patients achieving very low LDL-C levels
have been shown to be at very low CVD risk, although
the number of patients achieving such very low levels
in any given single trial is usually small (4–6).
The guideline-recommendedmarker of atherogenic
lipoproteins is LDL-C, but we have recently shown that
among patients treated with statin therapy, non–high-rans Health Care System, San Antonio, Texas; yyyMedical Resear
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487very low LDL-C, non-HDL-C, or apoB levels and the
risk for major cardiovascular events.
METHODS
STUDY ELIGIBILITY AND DATA COLLECTION. The
methods of this meta-analysis have been described
previously (7). The published reports were searched
to identify all randomized controlled trials that
assigned study participants in at least 1 of the study
groups to statin therapy, and that measured total
cholesterol, LDL-C, high-density lipoprotein choles-
terol (HDL-C), triglycerides, and apolipoproteins at
baseline and during statin therapy in the entire study
population. Trials with a mean follow-up for cardio-
vascular events <2 years and those including <1,000
participants were excluded. The search of published
reports was undertaken in PubMed using the
following search terms: statin, hydroxymethylglutaryl
coenzyme A reductase inhibitor, simvastatin, lova-
statin, ﬂuvastatin, pravastatin, atorvastatin, rosuva-
statin, cholesterol, apolipoprotein, coronary heart
disease, coronary artery disease, and CVD. The results
were limited to randomized trials in English. The ﬁrst
search was performed on January 4, 2009, and an
updated search that extended until December 31,
2011, was performed on January 20, 2012. Two au-
thors (S.M.B., B.J.A.) independently screened all ab-
stracts for randomized controlled trials fulﬁlling the
inclusion criteria. If an abstract described a sub-
analysis of a potentially relevant trial, the original
publication was traced. Results were compared and
inconsistencies were resolved by consensus.
Investigators were contacted and asked to provide
individual patient data. The requested patient char-
acteristics included sex; age; smoking status; body
mass index; diabetes mellitus status; systolic and
diastolic blood pressure; fasting glucose, total
cholesterol, LDL-C, HDL-C, triglycerides, and apo A-Iconsulting fees from Roche Products Ltd., Janssen Pharmaceuticals, Inc., Ko
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up; study medications; and patients’ histories of
stable coronary heart disease (CHD), myocardial
infarction (MI), percutaneous coronary intervention,
and coronary artery bypass grafting. The following
outcomes (and times to events) were also collected:
fatal and nonfatal MI, fatal “other CHD,” hospi-
talization for unstable angina, fatal and nonfatal
stroke, fatal and nonfatal hemorrhagic stroke, pe-
ripheral artery disease, and congestive heart failure.
Data were harmonized into a pooled database that
was independently validated against the original
ﬁles. The Delphi score assessed the quality of the
included trials (11). This meta-analysis followed the
Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines, and a
checklist was provided at the time of manuscript
submission (12).
LIPIDS, APOLIPOPROTEINS, STATINS, AND OUTCOME
DEFINITIONS. Lipid and apo levels at baseline and at 1-
year follow-up were obtained from the participating tri-
als. For on-statin measurements, the 1-year time point
was chosen because it was the ﬁrst uniform time point
when apolipoproteins weremeasured in all participating
trials. Cholesterol levels reported in mmol/l were con-
verted to mg/dl by multiplying by 38.7, and triglycerides
levels reported in mmol/l were converted to mg/dl by
multiplyingby88.5.High-dose statin therapywasdeﬁned
as either atorvastatin80mgor rosuvastatin 20mg.Usual-
dose statin therapywas deﬁned as all other statin dosing
regimens. The primary outcome of this meta-analysis
was time to ﬁrst major cardiovascular event, deﬁned as
fatal or nonfatalMI, fatal “otherCHD,”hospitalization for
unstable angina, or fatal or nonfatal stroke. Subanalyses
were performed for the prediction of time to ﬁrst major
coronary event (fatal or nonfatal MI, fatal “other CHD,”
and hospitalization for unstable angina) and time to ﬁrst
major cerebrovascular event (fatal or nonfatal stroke).wa Pharmaceuticals America, Inc., Merck & Co., Inc.,
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488STATISTICAL ANALYSIS. Baseline characteristics,
levels of lipids and apolipoproteins at baseline and
at 1 year, as well as absolute changes and percent
changes between on-trial and baseline levels were
calculated for each trial separately. The distributions
of percent LDL-C, non-HDL-C, or apoB reduction
were displayed in waterfall plots for several exam-
ples of statin-trial arms with a ﬁxed-dose increase, as
well as for an example of patients enrolled in a pla-
cebo arm to represent the natural variability of
these parameters. To limit the effect of potential
outliers, patients with levels >5 SDs of the mean were
excluded. The proportion of study participants not
achieving an on-trial LDL-C target of <100 mg/dl
or <70 mg/dl was calculated among those random-
ized to high-dose statin therapy in 1 of the included
trials. Similar proportions were calculated for a non-
HDL-C target of <130 mg/dl or <100 mg/dl, and for
an apoB target of <100 mg/dl or <80 mg/dl. The as-
sociation between on-statin achieved levels of LDL-C,
non-HDL-C, or apoB and the risk of cardiovascular
events was evaluated using the Cox proportional
hazards model. For these analyses, study participants
allocated to placebo were excluded. Hazard ratios
(HRs) and corresponding 95% conﬁdence intervals
(CIs) for the risks for cardiovascular events were
calculated by categories of achieved LDL-C, non-
HDL-C, and apoB levels, using the highest category as
reference. LDL-C category cut-offs were chosen as
follows: 50, 75, 100, 125, 150, and 175 mg/dl. We also
speciﬁcally tested whether the risk for major car-
diovascular events was lower among patients
achieving very low LDL-C levels (<50 mg/dl)
compared with those achieving moderately low
levels (75 to <100 mg/dl). Equivalent analyses using
LDL-C cutoffs <50, <70, <100, <130, <160, and <190
mg/dl, as well as using non-HDL-C cutoffs 30 mg/dl
higher, also were performed. Analyses were adjusted
for sex, age, smoking status, diabetes mellitus status,
systolic blood pressure, HDL-C, and trial. Analyses
were not additionally adjusted for prevalent CHD
because all trials enrolled either 0% or 100% patients
with prevalent disease, so adjustment for trial im-
plies adjustment for prevalent CHD. However, prev-
alent CHD as an inclusion criterion was documented
less rigorously in some trials than in other trials.
Separate analyses for the outcomes of major cardio-
vascular events, major coronary events, major cere-
brovascular events, and hemorrhagic stroke were
performed.
Statistical heterogeneity across trials was quanti-
ﬁed using the Cochran Q statistic and the I2 statistic.
The I2 statistic was derived from the Q statistic
([Q  df/Q]  100) and provides a measure of theproportion of the overall variation attributable to
between-study heterogeneity (13). The potential for
publication bias was addressed by drawing funnel
plots and visual assessment. Proportionality of haz-
ards over time was graphically checked by plotting
the cumulative hazards over time for all categories
against each other. A 2-tailed p value of <0.05 was
considered statistically signiﬁcant. Statistical ana-
lyses were performed using SPSS version 20.0 (IBM
SPSS Statistics, IBM Corporation, Armonk, New York).
RESULTS
The results of the literature search are shown in
Online Figure 1 and have been published previously
(7). Individual patient data were obtained from all 8
trials (14–21), with the exception of those on hemor-
rhagic stroke, which were not available from
AFCAPS-TexCAPS (Air Force/Texas Coronary Athero-
sclerosis Prevention Study) (15). The study charac-
teristics of these 8 trials are shown in Online Table 1.
Trials were of high quality, with a median Delphi
score of 9 (range 6 to 9). Heterogeneity between trials
with regard to the association with risk for major
cardiovascular events was low for LDL-C (Q ¼ 6.94;
p ¼ 0.4; I2 ¼ 0%), non-HDL-C (Q: 6.05; p ¼ 0.53; I2 ¼
0%), and apoB (Q ¼ 9.55; p ¼ 0.2; I2 ¼ 26%), as re-
ported previously (7). Visual assessment of funnel
plots did not suggest strong evidence for bias. The
proportionality assumptions were satisﬁed.
The baseline characteristics of the study partici-
pants are shown in Online Table 2. Levels of lipids
and apolipoproteins at baseline and at 1 year on-trial,
as well as the absolute and percent changes between
baseline and on-trial levels, are shown in Online
Table 3. A total of 38,153 study participants were
randomized to a statin arm and had a complete set of
lipid and apo levels during statin treatment available.
During 155,573 person-years of follow-up, 158 study
participants (0.4%) developed a fatal MI, and 1,678
(4.4%) developed a nonfatal MI. Fatal “other CHD”
occurred in 615 study participants (1.6%), and fatal or
nonfatal stroke occurred in 1,029 study participants
(2.7%). A total of 2,806 participants (7.4%) were
hospitalized for unstable angina. A total of 5,387
study participants (14.1%) developed at least 1 major
cardiovascular event. Of these, 4,577 experienced
1 event, 728 experienced 2 events, 75 experienced
3 events, and 7 experienced 4 events.
Waterfall plots of the distribution of percent LDL-C
reduction ([1 year – baseline]/[baseline]) achieved in
various trials are shown in Figure 1. Displayed are
typical examples of the initiation of usual-dose statin
therapy (patients assigned to pravastatin 40 mg in
A B
C D
FIGURE 1 Waterfall Plots of Percent LDL-C Reduction
Waterfall plots presenting the distribution of percent reduction in low-density lipoprotein
cholesterol (LDL-C) ([1 year – baseline]/baseline) achieved in trials. Displayed are typical
examples of usual-dose statin therapy (pravastatin 40 mg in the LIPID [Long-Term
Intervention With Pravastatin in Ischemic Disease] trial [3]) (A), high-dose statin therapy
(rosuvastatin 20 mg in the JUPITER [Justiﬁcation for the Use of Statins in Prevention: an
Intervention Trial Evaluating Rosuvastatin] trial [6]) (B), a dose increase from usual-dose
to high-dose statin therapy (atorvastatin, from 10 to 80 mg, in the TNT [Treating to New
Targets] trial [5]) (C), and a placebo arm (AFCAPS-TexCAPS [Air Force/Texas Coronary
Atherosclerosis Prevention Study] [15]) (D).
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489the LIPID [Long-Term Intervention With Pravastatin
in Ischemic Disease] trial [3]; n ¼ 3,936) (Fig. 1A),
the initiation of high-dose statin therapy (patients
assigned to rosuvastatin 20 mg in the JUPITER
[Justiﬁcation for the Use of Statins in Prevention: an
Intervention Trial Evaluating Rosuvastatin] trial [6];
n ¼ 7,783) (Fig. 1B), a dose increase from usual-dose
to high-dose statin (patients with atorvastatin dose
increased from 10 to 80 mg in the TNT [Treating to
New Targets] trial [5]; n ¼ 4,636) (Fig. 1C), and pa-
tients not treated with statin therapy (patients
enrolled in the placebo arm of AFCAPS-TexCAPS; n ¼
2,802) (Fig. 1D). The corresponding examples of non-
HDL-C reduction and apoB reduction are shown in
Online Figures 2 and 3, respectively. These waterfall
plots display a large interindividual variation with
regard to the reductions in LDL-C, non-HDL-C, and
apoB achieved with a ﬁxed-dose statin regimen.
Figure 2 presents the distribution of achieved
levels of LDL-C, non-HDL-C, and apoB among pa-
tients assigned to high-dose statin therapy (e.g.,
either atorvastatin 80 mg in TNT [5], IDEAL [High-
Dose Atorvastatin Vs. Usual-Dose Simvastatin for
Secondary Prevention After Myocardial Infarction]
[19], or SPARCL [Stroke Prevention by Aggressive
Reduction in Cholesterol Levels] [20] or rosuvastatin
20 mg in JUPITER [6]). Among 18,677 patients
assigned to high-dose statin therapy, the mean ach-
ieved LDL-C level was 69.6  27.0 mg/dl. A total of
2,364 (12.7%) did not reach an LDL-C target <100 mg/
dl, 7,546 (40.4%) did not reach an LDL-C target <70
mg/dl, and 14,600 (78.3%) did not reach an LDL-C
target <50 mg/dl. A total of 2,176 (11.7%) did not
reach a non-HDL-C level of <130 mg/dl, whereas
6,285 (33.7%) did not reach a non-HDL-C level
<100 mg/dl. The number of patients not reaching
apoB <100 mg/dl was 2,740 (14.7%), and the number
not reaching apoB <80 mg/dl was 6,662 (35.7%).
The risk estimates for cardiovascular events, by
categories of achieved LDL-C level, are presented
in Table 1. Patients achieving an LDL-C level<50mg/dl
had a signiﬁcantly lower risk for major cardiovascu-
lar events compared with those with an LDL-C
level $175 mg/dl (adjusted hazard ratio [HR] 0.44;
95% CI: 0.35 to 0.55). In fact, this category of patients
achieving an LDL-C <50 mg/dl had a statistically
signiﬁcantly lower risk for major cardiovascular
events even when compared with patients achieving
an LDL-C level between 75 and <100 mg/dl (adjusted
HR: 0.81; 95% CI: 0.70 to 0.95). Similarly, the risk for
major coronary events lowered with decreasing
categories of achieved LDL-C, such that patients
achieving an LDL-C level <50 mg/dl had an adjusted
HR of 0.47 (95% CI: 0.36 to 0.61) compared with thosewith an LDL-C level $175 mg/dl. The association be-
tween achieved LDL-C categories and the risk for
major cerebrovascular events was less linear than
for coronary events, although with a similar over-
all trend, such that patients achieving an LDL-C
level <50 mg/dl had an adjusted HR of 0.36 (95%
CI: 0.22 to 0.59) compared with those in the highest
category. Additional adjustment for baseline LDL-C
levels did not change these results importantly. The
corresponding results for non-HDL-C and apoB are
shown in Tables 2 and 3, respectively. Online Tables 4
and 5, respectively, show equivalent analyses using
the alternative LDL-C cutoffs of <50, <70, <100,
<130, <160, and <190 mg/dl and non-HDL-C cutoffs
of <80, <100, <130, <160, <190, and <220 mg/dl.
Online Table 6 shows the risk for hemorrhagic stroke,
by categories of LDL-C, non-HDL-C, and apoB, on
the basis of data available from 7 trials (excepting
AFCAPS-TexCAPS). Although the absolute number
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FIGURE 2 Distribution of Achieved Levels of LDL-C, Non-HDL-C, and ApoB
Histograms displaying the distribution of achieved levels of low-density lipoprotein
cholesterol (LDL-C) (A), non-high-density lipoprotein cholesterol (non-HDL-C) (B), and
apolipoprotein B (apoB) (C) among patients treated with high-dose statin therapy. The
results are on the basis of patients assigned to atorvastatin 80 mg in the TNT (Treating to
New Targets) (5), IDEAL (High-Dose Atorvastatin Vs. Usual-Dose Simvastatin for Sec-
ondary Prevention After Myocardial Infarction) (19), and SPARCL (Stroke Prevention by
Aggressive Reduction in Cholesterol Levels) (20) trials, and those assigned to rosuvastatin
20 arm in the JUPITER (Justiﬁcation for the Use of Statins in Prevention: an Intervention
Trial Evaluating Rosuvastatin) trial.
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490of hemorrhagic strokes was low and, therefore, sta-
tistical power was limited, the results suggest that
the risk for hemorrhagic stroke was somewhat higher
among patients achieving very low levels of athero-
genic lipoproteins compared with that in those
achieving moderately low levels.
DISCUSSION
Our results show that there is large interindividual
variation with regard to the reduction of atherogenic
lipoprotein levels achieved with statin therapy. As
a consequence, >40% of trial patients assigned to
high-dose statin therapy did not reach an LDL-C
level <70 mg/dl (Central Illustration). The clinical
beneﬁt of achieving even lower levels of atherogenic
lipoproteins appears to be considerable because pa-
tients achieving an LDL-C level <50 mg/dl are at
signiﬁcantly lower risk for major cardiovascular
events, even when compared with those reaching
LDL-C levels 75 to <100 mg/dl.
It is well-known that there is large interindividual
variation in the response to statin therapy. However,
our results highlight an underappreciated aspect,
namely, that some patients achieve a large reduction
of atherogenic lipoprotein levels, whereas others
respond poorly. Therefore, the current management
of dyslipidemia continues to be suboptimal (22).
Multiple patient characteristics, including sex, age,
smoking status, body weight, diet, and physical
activity have been reported to contribute to varia-
tions in statin-induced LDL-C reduction, but the
impact of these factors is modest (23–25). However,CENTRAL ILLUSTRATION On-Statin LDL-C Levels and Risk
for Major Cardiovascular Events
Distribution of achieved on-statin LDL-C levels (dark blue curve;
right y-axis) and the risk of major cardiovascular events (light
blue line; left y-axis). The x-axis represents achieved on-statin
LDL-C levels. LDL C ¼ low-density lipoprotein cholesterol; HR ¼
hazard ratio.
TABLE 1 Risk for Major Cardiovascular Events, by Achieved LDL-C Concentration
Achieved On-Trial LDL-C Concentration, mg/dl (mmol/l)
<50
(<1.29)
(n ¼ 4,375)
50–<75
(1.29–<1.94)
(n ¼ 10,395)
75–<100
(1.94–<2.58)
(n ¼ 10,091)
100–<125
(2.58–<3.23)
(n ¼ 8,953)
125–<150
(3.23–<3.88)
(n ¼ 3,128)
150–<175
(3.88–<4.52)
(n ¼ 836)
$175
($4.52)
(n ¼ 375)
Major cardiovascular events 194 (4.4) 1,185 (11.4) 1,664 (16.5) 1,480 (16.5) 557 (17.8) 184 (22.0) 123 (32.8)
Unadjusted HR (95% CI) 0.20 (0.16–0.25) 0.40 (0.33–0.48) 0.50 (0.42–0.60) 0.48 (0.40–0.58) 0.51 (0.42–0.62) 0.64 (0.51–0.81) 1.00 (ref)
Adjusted HR (95% CI)* 0.44 (0.35–0.55) 0.51 (0.42–0.62) 0.56 (0.46–0.67) 0.58 (0.48–0.69) 0.64 (0.53–0.79) 0.71 (0.56–0.89) 1.00 (ref)
Major coronary events 129 (2.9) 918 (8.8) 1,431 (14.2) 1,336 (14.9) 492 (15.7) 170 (20.3) 107 (28.5)
Unadjusted HR (95% CI) 0.15 (0.12–0.20) 0.36 (0.29–0.43) 0.50 (0.41–0.61) 0.51 (0.42–0.62) 0.53 (0.43–0.65) 0.69 (0.54–0.88) 1.00 (ref)
Adjusted HR (95% CI)* 0.47 (0.36–0.61) 0.53 (0.43–0.65) 0.58 (0.48–0.71) 0.62 (0.51–0.75) 0.67 (0.55–0.83) 0.78 (0.61–0.99) 1.00 (ref)
Major cerebrovascular events 72 (1.6) 315 (3.0) 302 (3.0) 205 (2.3) 91 (2.9) 21 (2.5) 23 (6.1)
Unadjusted HR (95% CI) 0.47 (0.29–0.74) 0.62 (0.41–0.95) 0.52 (0.34–0.79) 0.38 (0.25–0.58) 0.47 (0.30–0.75) 0.41 (0.23–0.74) 1.00 (ref)
Adjusted HR (95% CI)* 0.36 (0.22–0.59) 0.46 (0.30–0.71) 0.49 (0.32–0.75) 0.45 (0.29–0.69) 0.58 (0.36–0.91) 0.43 (0.24–0.78) 1.00 (ref)
Values are n (%) unless otherwise indicated. *Adjusted for sex, age, smoking status, presence of diabetes mellitus, systolic blood pressure, high-density lipoprotein cholesterol concentration, and trial.
The highest low-density lipoprotein cholesterol (LDL-C) category was used as the reference category.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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491nonadherence is probably one of the most important
factors in the failure of patients to reach their lipid
targets. Nonadherence is a complex entity and is
affected by several factors, including dose-related
toxicity and adverse effects, physician-related is-
sues, and patient-related issues such as depression
(26–28).
Several studies have investigated the association
between genetic variants and the magnitude of
LDL-C reduction achieved with a ﬁxed-dose statin.
For instance, among patients treated with prava-
statin 40 mg, 2 common variants in the 3-hydroxy-
3-methylglutaryl coenzyme A reductase gene
(HMGCR) were shown to have been associated with
lower efﬁcacy of pravastatin treatment (29). In a ge-
netic substudy of the TNT trial, variants of APOE,
PCSK9, and HMGCR also were associated with statin
efﬁcacy, in this case atorvastatin (30). A genome-wideTABLE 2 Risk for Major Cardiovascular Events, by Achieved Non-HDL
Ac
<75
(<1.94)
(n ¼ 6,341)
75–<100
(1.94–<2.58)
(n ¼ 8,318)
Major cardiovascular events 390 (6.2) 970 (11.7)
Unadjusted HR (95% CI) 0.31 (0.26–0.38) 0.48 (0.41–0.57)
Adjusted HR (95% CI)* 0.57 (0.47–0.69) 0.60 (0.51–0.71)
Major coronary events 260 (4.1) 760 (9.1)
Unadjusted HR (95% CI) 0.24 (0.20–0.29) 0.44 (0.37–0.52)
Adjusted HR (95% CI)* 0.58 (0.47–0.72) 0.61 (0.51–0.73)
Major cerebrovascular events 145 (2.3) 246 (3.0)
Unadjusted HR (95% CI) 0.72 (0.49–1.06) 0.71 (0.49–1.03)
Adjusted HR (95% CI)* 0.49 (0.33–0.73) 0.55 (0.37–0.80)
Values are n (%) unless otherwise indicated. *Adjusted for sex, age, smoking status, p
and trial. The highest non-HDL-C category was used as the reference category.
Abbreviations as in Table 1.association study in the JUPITER trial identiﬁed var-
iants of ABCG2, LPA, APOE, and PCSK9 to be involved
in response to rosuvastatin (31). Voora et al. (32) re-
ported that variants in the APOE and ABCA1 genes
also were associated with statin efﬁcacy. Overall, the
lack of strong genetic effects on statin-induced lipid
response in these large trials is likely a reﬂection of
the complexity of lipid homeostasis and suggests
that variability in response is due to a range of
small effects superimposed on nonadherence (30).
Thus, the most important causes of inadequate lipid
lowering achieved with statin therapy are largely
unexplained.
The U.S. Executive Summary of the Third Report
of the National Cholesterol Education Program
Expert Panel on Detection, Evaluation, And Treat-
ment of High Blood Cholesterol In Adults guideline
(33) recommends that for patients with CHD or-C Concentration
hieved On-Trial Non-HDL-C Concentration, mg/dl (mmol/l)
100–<125
(2.58–<3.23)
(n ¼ 9,764)
125–<150
(3.23–<3.88)
(n ¼ 7,956)
150–<175
(3.88–<4.52)
(n ¼ 3,992)
175–<200
(4.52–<5.17)
(n ¼ 1,178)
‡200
(‡5.17)
(n ¼ 604)
1,555 (15.9) 1,349 (17.0) 697 (17.5) 259 (22.0) 167 (27.6)
0.59 (0.50–0.69) 0.60 (0.51–0.71) 0.61 (0.52–0.72) 0.80 (0.66–0.97) 1.00 (ref)
0.64 (0.54–0.75) 0.69 (0.59–0.81) 0.75 (0.63–0.89) 0.89 (0.73–1.08) 1.00 (ref)
1,338 (13.7) 1,220 (15.3) 627 (15.7) 232 (19.7) 146 (24.2)
0.59 (0.49–0.69) 0.63 (0.53–0.75) 0.64 (0.53–0.76) 0.82 (0.67–1.01) 1.00 (ref)
0.66 (0.56–0.79) 0.73 (0.62–0.87) 0.79 (0.66–0.94) 0.94 (0.76–1.15) 1.00 (ref)
278 (2.8) 191 (2.4) 100 (2.5) 38 (3.2) 31 (5.1)
0.59 (0.41–0.86) 0.47 (0.33–0.69) 0.49 (0.33–0.73) 0.64 (0.40–1.02) 1.00 (ref)
0.54 (0.37–0.79) 0.54 (0.37–0.79) 0.59 (0.40–0.89) 0.68 (0.42–1.10) 1.00 (ref)
resence of diabetes mellitus, systolic blood pressure, high-density lipoprotein cholesterol (HDL-C) concentration,
TABLE 3 Risk for Major Cardiovascular Events, by Achieved ApoB Concentration
Achieved On-Trial apoB Concentration, mg/dl
<50
(n ¼ 1,278)
50–<75
(n ¼ 10,085)
75–<100
(n ¼ 12,989)
100–<125
(n ¼ 9,769)
125–<150
(n ¼ 2,969)
150–<175
(n ¼ 824)
‡175
(n ¼ 239)
Major cardiovascular events 43 (3.4) 942 (9.3) 1,846 (14.2) 1,676 (17.2) 606 (20.4) 209 (25.4) 65 (27.2)
Unadjusted HR (95% CI) 0.21 (0.14–0.30) 0.41 (0.32–0.52) 0.51 (0.40–0.66) 0.61 (0.47–0.78) 0.72 (0.56–0.93) 0.94 (0.71–1.25) 1.00 (ref)
Adjusted HR (95% CI)* 0.59 (0.40–0.88) 0.55 (0.43–0.71) 0.59 (0.46–0.76) 0.64 (0.50–0.82) 0.71 (0.55–0.92) 0.91 (0.69–1.20) 1.00 (ref)
Major coronary events 30 (2.3) 723 (7.2) 1,573 (12.1) 1,483 (15.2) 531 (17.9) 186 (22.6) 57 (23.8)
Unadjusted HR (95% CI) 0.16 (0.11–0.25) 0.36 (0.27–0.47) 0.51 (0.39–0.66) 0.62 (0.47–0.80) 0.73 (0.55–0.96) 0.96 (0.71–1.29) 1.00 (ref)
Adjusted HR (95% CI)* 0.59 (0.37–0.93) 0.54 (0.41–0.70) 0.58 (0.45–0.76) 0.64 (0.49–0.83) 0.70 (0.53–0.92) 0.91 (0.68–1.22) 1.00 (ref)
Major cerebrovascular events 14 (1.1) 256 (2.5) 347 (2.7) 264 (2.7) 102 (3.4) 31 (3.8) 15 (6.3)
Unadjusted HR (95% CI) 0.34 (0.16–0.70) 0.52 (0.31–0.87) 0.44 (0.26–0.73) 0.43 (0.25–0.72) 0.53 (0.31–0.92) 0.60 (0.32–1.11) 1.00 (ref)
Adjusted HR (95% CI)* 0.45 (0.21–0.95) 0.49 (0.29–0.83) 0.51 (0.31–0.86) 0.52 (0.31–0.88) 0.61 (0.35–1.04) 0.61 (0.33–1.13) 1.00 (ref)
Values are n (%) unless otherwise indicated. *Adjusted for sex, age, smoking status, presence of diabetes mellitus, systolic blood pressure, HDL-C concentration, and trial. The highest apolipoprotein B
(apoB) category was used as the reference category.
Abbreviations as in Tables 1 and 2.
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492a CHD risk equivalent, the LDL-C goal should
be <100 mg/dl. The more recently published Euro-
pean guidelines recommend that for people at high
CVD risk, the LDL-C goal is <2.5 mmol/l (w100 mg/dl)
(34). These guidelines also suggest a target of
<70 mg/dl or <1.8 mmol/l, respectively, for patients
at very high CVD risk, but these recommendations
are not evidence based. Our results suggest that
even in the optimal setting of a randomized
controlled trial, >40% of patients assigned to high-
dose statin therapy do not reach an LDL-C level
<70 mg/dl. However, Phase 2 data from trials of
PCSK9 inhibitors suggest that the large majority of
patients treated with those agents may be able to
reach LDL-C levels <70 mg/dl (8).
Whether achieving very low levels of atherogenic
lipoproteins is indeed beneﬁcial in terms of CVD
risk is unclear. Post-hoc analyses of data from
several statin trials have shown that patients
achieving very low LDL-C levels on statin therapy
are at lower CVD risk than are those achieving
moderately low levels, although the number of pa-
tients achieving very low LDL-C levels in individual
trials is usually small. As reported in a substudy of
the PROVE IT–TIMI 22 (Pravastatin or Atorvastatin
Evaluation and Infection Therapy–Thrombolysis In
Myocardial Infarction 22) trial, there was no adverse
effect and even an apparently lower cardiovascular
risk in patients who reached LDL-C levels lower
than the target 80 to <100 mg/dl (4). A post-hoc
analysis of data from the TNT trial showed that
there was a signiﬁcant reduction in the rate of
major cardiovascular events with descending quin-
tiles of achieved on-treatment LDL-C, even down
to the lowest quintile, which was deﬁned as <64
mg/dl (5). In JUPITER (6), statin-allocated participantsattaining LDL-C <50 mg/dl had a lower risk for
cardiovascular events than did those not reaching
LDL-C <50 mg/dl. Our large-scale meta-analysis
supports the results of those studies and suggests
that achieving very low levels of atherogenic lipo-
proteins seems to provide cardiovascular beneﬁt
beyond just treatment with a statin. With regard to
the safety of very low levels of atherogenic lipo-
proteins, we observed that the risk for hemorrhagic
stroke appeared to be somewhat higher among pa-
tients achieving very low levels of atherogenic li-
poproteins than among those achieving moderately
low levels. However, the number of hemorrhagic
strokes was low, so statistical power was insufﬁ-
cient to draw deﬁnite conclusions, and this small
potential relative increase in hemorrhagic stroke
was outweighed by a much lower risk for other
cerebrovascular events. Thus, the overall risk for
major cerebrovascular events was still lowest among
patients achieving very low levels of atherogenic
lipoproteins.
Several aspects need to be taken into account
when interpreting the results of this analysis. An
important strength of this study was the availability
of individual patient data, which enabled individual-
level patient analyses, which in turn provide more
appropriate and accurate results than do study-level
analyses. A second strength was the fact that the
dataset contained large numbers of patients and
major cardiovascular events, allowing for more reli-
able analyses of the relatively small group of pa-
tients reaching very low levels of atherogenic
lipoproteins, which in individual trials is usually a
small number.
STUDY LIMITATIONS. The most important limitation
was the fact that this was a post-hoc analysis on
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: High-dose statin
therapy reduces blood levels of atherogenic lipoproteins and the
risk for cardiovascular events more than does intermediate-dose
therapy, but the value of targeting speciﬁc lipoprotein levels is
uncertain.
TRANSLATIONAL OUTLOOK: Randomized trials are needed
to test the efﬁcacy and safety of targeting speciﬁc blood levels
of lipoproteins to reduce cardiovascular risk.
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493the basis of observational data, which cannot be
extrapolated to treatment recommendations. A sec-
ond limitation was the fact that the participating tri-
als had different inclusion criteria. The different
distributions of baseline characteristics may have
affected the results of our meta-analysis. In partic-
ular, inclusion on the basis of lipid criteria may have
led to the selection of speciﬁc subpopulations of
patients in some trials. In addition, outcome deﬁni-
tions may have differed slightly between trials. The
results were on the basis of patients included in tri-
als, and these results cannot necessarily be extra-
polated to patients in routine clinical practice.
Another limitation was the use of on-statin lipid and
apolipoprotein levels measured at 1-year follow-up.
This time point was chosen because it was the ﬁrst
uniform time point when lipids and apolipoproteins
were measured in all participating trials. Therefore,
fatal cardiovascular events occurring in the ﬁrst year
of therapy are not accounted for in this analysis.
Finally, part of the variability of LDL-C reductions
observed in the trials may not have a strict biological
explanation but also could be explained by drug in-
teractions or other factors, such as noncompliance—a
factor that could not be accounted for in the present
analysis.
CONCLUSIONS
We show that large interindividual variability
exists with regard to the reduction of atherogeniclipoprotein levels achieved with statin therapy,
and that despite treatment with high-dose statin
therapy, >40% of trial patients do not reach
guideline-recommended targets. Importantly, pa-
tients who achieve an LDL-C level <50 mg/dl are at
lower CVD risk than are those achieving an LDL-C
level 75 to <100 mg/dl. Whether a strategy targeting
very low levels of atherogenic lipoproteins provides
clinical beneﬁt compared with a strategy targeting
moderately low levels needs to be established in
randomized controlled trials.
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